论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
补肺益肾颗粒减少 GOLD 3-4 级慢性阻塞性肺病患者的急性加重:一项随机对照试验
Authors Yu XQ, Di JQ, Zhang W, Wei GS, Ma ZP, Wu L, Yu XF, Zhu HZ, Zhou M, Feng CL, Feng JH, Fan P, Li JS , Yang JY
Received 10 May 2023
Accepted for publication 17 October 2023
Published 6 November 2023 Volume 2023:18 Pages 2439—2456
DOI https://doi.org/10.2147/COPD.S413754
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Purpose: Chronic obstructive pulmonary disease (COPD) is a disease characterized by frequent acute exacerbations (AEs), especially in severe and very severe cases. We aimed to evaluate the efficacy and safety of Bu-fei Yi-shen granules (BYGs) for COPD.
Patients and Methods: We conducted a multicenter, randomized, double-blinded, placebo-controlled trial of 348 COPD patients with GOLD 3– 4 COPD. The patients were randomly assigned into experimental or control groups in a 1:1 ratio. Patients in the experimental group were prescribed BYG, while those in the control group were administered a placebo, orally, twice daily, with 5 days on and 2 days off per week for 52 weeks. The outcomes included AEs, pulmonary function, clinical signs and symptoms, dyspnea scores (mMRC), quality of life scores, and a 6-minute walk test (6MWT).
Results: A total of 280 patients completed the trial, including 135 patients in the experimental group and 145 in the control group. Compared to the control group, significant differences were observed in frequencies of AEs (mean difference: − 0.35; 95% CI: − 0.61, − 0.10; P = 0.006) and AE-related hospitalizations (− 0.18; 95% CI: − 0.36, − 0.01; P = 0.04), 6MWD (40.93 m; 95% CI: 32.03, 49.83; P < 0.001), mMRC (− 0.57; 95% CI: − 0.76, − 0.37; P < 0.001), total symptoms (− 2.18; 95% CI: − 2.84, − 1.53; P < 0.001), SF-36 (11.60; 95% CI: 8.23, 14.97; P < 0.001), and mCOPD-PRO (− 0.45; 95% CI: − 0.57, − 0.33; P < 0.001) after treatment. However, there were no significant differences in mortality, pulmonary function, and mESQ-PRO scores (P > 0.05). No obvious adverse events were observed.
Conclusion: BYG, as compared to a placebo, could significantly reduce the frequencies of AEs and AE-related hospitalizations for GOLD 3– 4 COPD patients. Clinical symptoms, treatment satisfaction, quality of life, and exercise capacity improved. There was no significant improvement in mortality and pulmonary function.
Keywords: chronic obstructive pulmonary disease, traditional Chinese medicine, efficacy, safety, RCT